Chimeric Therapeutics Ltd begins collaboration with Sarah Cannon Research Institute for glioblastoma clinical trial
Chimeric Therapeutics Ltd (ASX:CHM), the only ASX clinical-stage cell therapy company, welcomes the participation of leading US centre Sarah Cannon Research...
Source: proactiveinvestors.com.au